Pilot study of NKTR214 and nivolumab in patients with sarcomas.

Volume: 37, Issue: 15_suppl, Pages: 11010 - 11010
Published: May 20, 2019
Abstract
11010 Background: Monotherapy checkpoint inhibitors have minimal efficacy in most patients with metastatic sarcoma. NKTR-214 is a CD122-preferential IL-2 pathway agonist that activates and expands natural killer and CD8+ T cells. Phase I/II data demonstrated the safety and efficacy of nivolumab plus NKTR-214 in multiple tumor types. A trial of NKTR-214 plus nivolumab was initiated in patients with selected sarcomas. Methods: This is a...
Paper Details
Title
Pilot study of NKTR214 and nivolumab in patients with sarcomas.
Published Date
May 20, 2019
Volume
37
Issue
15_suppl
Pages
11010 - 11010
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.